002393SZSE

Audit Report on the Implementation of Performance Commitments of Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd.

✨ AI Summary

This report audits the implementation of performance commitments by Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. The company's net profit after deducting non-recurring items for 2023, 2024, and 2025 exceeded the promised targets, with completion rates of 101.80%, 108.89%, and 114.65% respectively. The audit confirms the fairness of the disclosed information regarding the performance commitment realization.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_documentSign In to Upgrade

Audit Report on the Implementation of Performance Commitments of Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd.

Da Hua Audit No. [2026] 0011002915

To all shareholders of Tianjin Lisheng Pharmaceutical Co., Ltd.:

We have audited the accompanying "Explanation on the Implementation of Performance Commitments of Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd." (hereinafter referred to as "Lisheng Pharmaceutical Company") prepared by Lisheng Pharmaceutical Company.

I. Management's Responsibility

In accordance with the "Administrative Measures for Major Asset Restructuring of Listed Companies" and relevant regulatory guidelines issued by the China Securities Regulatory Commission, it is the responsibility of Lisheng Pharmaceutical Company's management to prepare the "Explanation on the Implementation of Performance Commitments of Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd.", ensuring that its content is true, accurate, and complete, and that it does not contain any false records, misleading statements, or significant omissions.

II. Certified Public Accountant's Responsibility

Our responsibility is to express an opinion on the "Explanation on the Implementation of Performance Commitments of Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd." prepared by the management of Lisheng Pharmaceutical Company, based on our assurance engagement. We performed this assurance engagement in accordance with the "Chinese Certified Public Accountants' Assurance Engagement Standards No. 3101 – Assurance Engagements Other Than Audits or Reviews of Historical Financial Information". This standard requires us to plan and perform the assurance engagement to obtain reasonable assurance about whether the "Explanation on the Implementation of Performance Commitments of Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd." is free from material misstatement. During the assurance engagement, we performed audit procedures, including the examination of accounting records, as we considered necessary. We believe that our assurance work provides a reasonable basis for our opinion.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.